Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
ST-266 by Noveome Biotherapeutics for Necrotizing Enterocolitis: Likelihood of Approval
ST-266 is under clinical development by Noveome Biotherapeutics and currently in Phase II for Necrotizing Enterocolitis. According to GlobalData, Phase...